NCT03680794Recruiting
Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test. The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 15 May 2018
- Start date
- 27 Jun 2018
- Primary completion date
- 27 Dec 2027
- Lead sponsor
- CHU de Reims
- Diseases
- Diabetic eye disease
- NCT number
- NCT03680794
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 27 Jun 2018 to the primary completion date, 27 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- over 18 years old
- with social security affiliation
- willing to participate this study non-inclusion criteria :
- any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids, or immunosuppressive agents
- any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation
- any serious allergy to the fluorescein sodium for injection in angiography
- any history of previous systemic anti-VEGF treatment
- any history of inflammatory or auto-immune disease
- any active extraocular inflammation or infection in the last 4 weeks before surgery exclusion criteria :
- Patients with C-reactive protein CRP \> 10mg/mL (serum sampling during surgery)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Reims Coordinator of this site? Confirm its status | Reims | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.